trending Market Intelligence /marketintelligence/en/news-insights/trending/jvi1fk6lmah6zja8jx3-lq2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Impax to pay $20M to consumers, insurers in Solodyn antitrust case

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Impax to pay $20M to consumers, insurers in Solodyn antitrust case

Impax Laboratories Inc. agreed to pay $20 million to consumers and insurers to resolve claims in an antitrust lawsuit related to Valeant Pharmaceuticals International Inc.'s acne medication Solodyn, Reuters reported.

The lawsuit, a portion of which was settled by the Hayward, Calif.-based pharmaceutical company earlier this month, alleged that Impax was involved in a pay-for-delay deal which kept cheaper versions of Solodyn from entering the market.

The accord was disclosed in papers filed in federal court in Boston, the news outlet added.